Molluscum contagiosum (MC) is a common viral infection that affects the skin of children. This study compared demographic data and treatment patterns for MC patients across US medical specialties. Using the National Ambulatory Medical Care Survey database from 2000 to 2016, we found an average of 471,383 pediatric MC visits yearly. Most visits were made by Caucasians (91.0%) or non-Hispanics (82.9%). Pediatricians handled most cases (46.5%), followed by dermatologists (36.8%) and family medicine physicians (10.6%). Dermatologists saw more Caucasian patients (95% vs. 84%) and more patients with private insurance (83% vs. 73%) than pediatricians. Patients living in non-metropolitan areas were more likely to visit family medicine physicians (55.0%) than pediatricians (26.4%) or dermatologists (16.3%). Pediatricians favored spontaneous resolution (70%) over dermatologists (38%). Pediatricians mainly used terpenoids (12%), steroids (4%), and imiquimod (4%), while dermatologists preferred terpenoids (20%), imiquimod (12%), and curettage (10%). Pediatricians oversee most MC cases, but treatment strategies significantly differ from the best-practice guidelines.
{"title":"Analysis of pediatric outpatient visits uncovers disparities in molluscum contagiosum treatment across medical specialties in the United States","authors":"Karan Rajalingam, Wei-Shen Chen, Ann Lin","doi":"10.4081/dr.2023.9851","DOIUrl":"https://doi.org/10.4081/dr.2023.9851","url":null,"abstract":"Molluscum contagiosum (MC) is a common viral infection that affects the skin of children. This study compared demographic data and treatment patterns for MC patients across US medical specialties. Using the National Ambulatory Medical Care Survey database from 2000 to 2016, we found an average of 471,383 pediatric MC visits yearly. Most visits were made by Caucasians (91.0%) or non-Hispanics (82.9%). Pediatricians handled most cases (46.5%), followed by dermatologists (36.8%) and family medicine physicians (10.6%). Dermatologists saw more Caucasian patients (95% vs. 84%) and more patients with private insurance (83% vs. 73%) than pediatricians. Patients living in non-metropolitan areas were more likely to visit family medicine physicians (55.0%) than pediatricians (26.4%) or dermatologists (16.3%). Pediatricians favored spontaneous resolution (70%) over dermatologists (38%). Pediatricians mainly used terpenoids (12%), steroids (4%), and imiquimod (4%), while dermatologists preferred terpenoids (20%), imiquimod (12%), and curettage (10%). Pediatricians oversee most MC cases, but treatment strategies significantly differ from the best-practice guidelines.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Rovaris, Giuseppe La Rosa, Sara Mezzana, Francesco Tonon, Luigi Mori, Eugenio Monti, Giuseppe Mazzeo, Piergiacomo Calzavara-Pinton, Mariachiara Arisi
We present a case of erythropoietic protoporphyria (EPP) in a 21-year-old man who sought medical attention in April 2022 due to diffuse edema and erythema of the hands, which he had been experiencing since childhood and occurring shortly after sun exposure. The patient's medical history revealed a partial deletion of the long arm of chromosome 18. Based on the patient's medical background and clinical symptoms, we conducted various tests, including measuring total erythrocyte protoporphyrin levels and evaluating the fluorometric emission peak of plasma porphyrins using a spectrofluorometer. Additionally, a genetic analysis revealed a complete deletion of the FECH gene on one allele and the presence of an intronic variant on the other allele, identified as c.315–48T>C (IVS3–48T>C) and classified as a susceptibility polymorphism. In June 2022, the patient underwent an Afamelanotide implant, which resulted in an improvement in his clinical condition.
{"title":"When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome 18 deletion","authors":"Sara Rovaris, Giuseppe La Rosa, Sara Mezzana, Francesco Tonon, Luigi Mori, Eugenio Monti, Giuseppe Mazzeo, Piergiacomo Calzavara-Pinton, Mariachiara Arisi","doi":"10.4081/dr.2023.9784","DOIUrl":"https://doi.org/10.4081/dr.2023.9784","url":null,"abstract":"We present a case of erythropoietic protoporphyria (EPP) in a 21-year-old man who sought medical attention in April 2022 due to diffuse edema and erythema of the hands, which he had been experiencing since childhood and occurring shortly after sun exposure. The patient's medical history revealed a partial deletion of the long arm of chromosome 18. Based on the patient's medical background and clinical symptoms, we conducted various tests, including measuring total erythrocyte protoporphyrin levels and evaluating the fluorometric emission peak of plasma porphyrins using a spectrofluorometer. Additionally, a genetic analysis revealed a complete deletion of the FECH gene on one allele and the presence of an intronic variant on the other allele, identified as c.315–48T>C (IVS3–48T>C) and classified as a susceptibility polymorphism. In June 2022, the patient underwent an Afamelanotide implant, which resulted in an improvement in his clinical condition.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135786171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Carolina De Almeida Figueiredo, Ana Luísa Matos, Joana Calvão, José Carlos Cardoso
To the Editor, Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder in which a reduced activity of nicotinamide dinucleotide phosphate (NAPDH) oxidase leads to defective reactive oxygen intermediates (ROS) and impairs intracellular killing of microorganisms. Patients have recurrent bacterial and fungal infections as well as granuloma formations, and have a higher risk of autoimmune and inflammatory disorders like lupus erythematosus.1 A 20-year-old caucasian male with a diagnosis of autosomal recessive CGD was referred to our hospital because of a pruritic photosensitive rash on the face and hands, present for more than a year. [...]
{"title":"Discoid lupus erythematosus associated with chronic granulomatous disease","authors":"Ana Carolina De Almeida Figueiredo, Ana Luísa Matos, Joana Calvão, José Carlos Cardoso","doi":"10.4081/dr.2023.9837","DOIUrl":"https://doi.org/10.4081/dr.2023.9837","url":null,"abstract":"To the Editor, Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder in which a reduced activity of nicotinamide dinucleotide phosphate (NAPDH) oxidase leads to defective reactive oxygen intermediates (ROS) and impairs intracellular killing of microorganisms. Patients have recurrent bacterial and fungal infections as well as granuloma formations, and have a higher risk of autoimmune and inflammatory disorders like lupus erythematosus.1 A 20-year-old caucasian male with a diagnosis of autosomal recessive CGD was referred to our hospital because of a pruritic photosensitive rash on the face and hands, present for more than a year. [...]","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135781753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Savoia, Matelda Medri, Davide Melandri, Lucia Domeniconi, Emilia Crisanti, Andrea Sechi, Ignazio Stanganelli
Cutaneous sebaceous carcinoma can be classified into periocular and extraocular and can occur as part of Muir Torre syndrome. It is usually a pink-red or yellow solitary nodule, mainly located in the head and neck region. According to the Literature, dermoscopy is characterized in most cases by yellow color, polymorphic vessels and ulceration. We performed a review of the Literature and we found 14 papers describing the dermoscopic features of 33 sebaceous carcinomas, to which we added a case that we have recently observed. Compared to the data of the Literature and in particular to the latest published reviews, we found that milky-red areas are frequently observed in CSC (47% of the cases) and can be added to the main dermoscopic features for the diagnosis. Histology showed, in our case, some features that were consistent with a cutaneous sebaceous carcinoma with a secretory pattern, and other features that were instead consistent with a non-secretory pattern. This was probably due to the fact that the lesion we observed was a moderately differentiated and not well-differentiated cutaneous sebaceous carcinoma. The presence of a cutaneous sebaceous carcinoma should always alert the clinician on the possible association with Muir-Torre syndrome and immunohistochemistry for mismatch repair genes defects can help in the diagnostic pathway.
{"title":"Extraocular cutaneous sebaceous carcinoma in a patient with Muir-Torre syndrome: special emphasis on histologic and dermoscopic features","authors":"Francesco Savoia, Matelda Medri, Davide Melandri, Lucia Domeniconi, Emilia Crisanti, Andrea Sechi, Ignazio Stanganelli","doi":"10.4081/dr.2023.9832","DOIUrl":"https://doi.org/10.4081/dr.2023.9832","url":null,"abstract":"Cutaneous sebaceous carcinoma can be classified into periocular and extraocular and can occur as part of Muir Torre syndrome. It is usually a pink-red or yellow solitary nodule, mainly located in the head and neck region. According to the Literature, dermoscopy is characterized in most cases by yellow color, polymorphic vessels and ulceration. We performed a review of the Literature and we found 14 papers describing the dermoscopic features of 33 sebaceous carcinomas, to which we added a case that we have recently observed. Compared to the data of the Literature and in particular to the latest published reviews, we found that milky-red areas are frequently observed in CSC (47% of the cases) and can be added to the main dermoscopic features for the diagnosis. Histology showed, in our case, some features that were consistent with a cutaneous sebaceous carcinoma with a secretory pattern, and other features that were instead consistent with a non-secretory pattern. This was probably due to the fact that the lesion we observed was a moderately differentiated and not well-differentiated cutaneous sebaceous carcinoma. The presence of a cutaneous sebaceous carcinoma should always alert the clinician on the possible association with Muir-Torre syndrome and immunohistochemistry for mismatch repair genes defects can help in the diagnostic pathway.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135780957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-13eCollection Date: 2024-09-02DOI: 10.4081/dr.2024.9837
Ana Carolina de Almeida Figueiredo, Ana Luísa Matos, Joana Calvão, José Carlos Cardoso
{"title":"Discoid lupus erythematosus associated with chronic granulomatous disease.","authors":"Ana Carolina de Almeida Figueiredo, Ana Luísa Matos, Joana Calvão, José Carlos Cardoso","doi":"10.4081/dr.2024.9837","DOIUrl":"10.4081/dr.2024.9837","url":null,"abstract":"","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"16 3","pages":"9837"},"PeriodicalIF":2.3,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal, diffuse, large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumen of small blood vessels, with no lymphadenopathy or masses. Herein, we report a cutaneous variant of IVLBCL that is rare in Asia. A healthy 73-year-old Japanese woman presented to our hospital with painful erythematous indurations and telangiectasia of the lower extremities, which was confirmed on dermoscopy. Physical examination revealed no systemic involvement, and laboratory parameters were within normal ranges. No abnormal FDG uptake was detected on 18FDG-PET/CT. Histopathological examination revealed proliferation and dilatation of blood vessels in the subcutis layer, occluded by CD20-positive atypical lymphoid cells. Thus, the patient was diagnosed with a cutaneous variant of IVLBCL without systemic symptoms. In conclusion, it is important to confirm telangiectasia using dermoscopy and perform skin biopsies in patients presenting with sudden-onset erythematous induration.
{"title":"A case of cutaneous variant of intravascular large B-cell lymphoma in which dermoscopy revealed telangiectasias associated with erythematous induration","authors":"Shigeru Koizumi, Yaei Togawa, Yuka Saeki, Ryo Shimizu, Michiyo Nakano","doi":"10.4081/dr.2023.9731","DOIUrl":"https://doi.org/10.4081/dr.2023.9731","url":null,"abstract":"Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal, diffuse, large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumen of small blood vessels, with no lymphadenopathy or masses. Herein, we report a cutaneous variant of IVLBCL that is rare in Asia. A healthy 73-year-old Japanese woman presented to our hospital with painful erythematous indurations and telangiectasia of the lower extremities, which was confirmed on dermoscopy. Physical examination revealed no systemic involvement, and laboratory parameters were within normal ranges. No abnormal FDG uptake was detected on 18FDG-PET/CT. Histopathological examination revealed proliferation and dilatation of blood vessels in the subcutis layer, occluded by CD20-positive atypical lymphoid cells. Thus, the patient was diagnosed with a cutaneous variant of IVLBCL without systemic symptoms. In conclusion, it is important to confirm telangiectasia using dermoscopy and perform skin biopsies in patients presenting with sudden-onset erythematous induration.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135785429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alba Guglielmo, Maria Ludovica Deotto, Luigi Naldi, Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi
This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.
{"title":"Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective","authors":"Alba Guglielmo, Maria Ludovica Deotto, Luigi Naldi, Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi","doi":"10.4081/dr.2023.9839","DOIUrl":"https://doi.org/10.4081/dr.2023.9839","url":null,"abstract":"This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135786172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Actinic prurigo (AP) is an uncommon photodermatosis. In European and native American populations, AP is more frequently found in young women and shows clinical improvement or remission in adulthood. The clinical symptoms of AP in Asians differ in that the condition usually occurs in adults (adult-onset AP) and is clinically persistent. The objective of this study is to investigate the characteristics and outcomes of patients with AP in Thailand. A total of 15 cases diagnosed AP were reviewed. All cases were adult-onset AP (mean age of onset was 45.5 years). Male predominated (66.7%). Mostly of them presented with papules on face and upper extremities. Mucositis was presented in 2 patients. Phototesting revealed decreased MED for UVA alone in 3 patients and decreased MED for both UVA and UVB in 3 patients. Nine patients who had normal MED were further performed photoprovocation test and showed positive UVA photoprovocation in 5 patients; positive both UVA and UVB photoprovocation in 4 patients. Systemic immunosuppressant was prescribed in 60% of patients. Median time to clinical improvement was 8.6 months. Complete clinical remission was found in only 3 patients. Adult-onset AP has different clinical features and responds differently to treatment, compared to classical AP.
{"title":"Exploring adult-onset actinic prurigo in Thailand","authors":"Siripan Sangmala, Chanisada Wongpraparat, Narumol Silpa-archa, Chayada Chaiyabutr","doi":"10.4081/dr.2023.9810","DOIUrl":"https://doi.org/10.4081/dr.2023.9810","url":null,"abstract":"Actinic prurigo (AP) is an uncommon photodermatosis. In European and native American populations, AP is more frequently found in young women and shows clinical improvement or remission in adulthood. The clinical symptoms of AP in Asians differ in that the condition usually occurs in adults (adult-onset AP) and is clinically persistent. The objective of this study is to investigate the characteristics and outcomes of patients with AP in Thailand. A total of 15 cases diagnosed AP were reviewed. All cases were adult-onset AP (mean age of onset was 45.5 years). Male predominated (66.7%). Mostly of them presented with papules on face and upper extremities. Mucositis was presented in 2 patients. Phototesting revealed decreased MED for UVA alone in 3 patients and decreased MED for both UVA and UVB in 3 patients. Nine patients who had normal MED were further performed photoprovocation test and showed positive UVA photoprovocation in 5 patients; positive both UVA and UVB photoprovocation in 4 patients. Systemic immunosuppressant was prescribed in 60% of patients. Median time to clinical improvement was 8.6 months. Complete clinical remission was found in only 3 patients. Adult-onset AP has different clinical features and responds differently to treatment, compared to classical AP.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135827803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Erythema Nodosum Leprosum (ENL) is an immunological complication of leprosy characterized by acute inflammation of the skin, nerves, and other organs. Identifying laboratory parameters are important to early diagnosis of leprosy reactions. Various cytokine biomarkers have been examined and only a few studies have reported on angiogenesis in leprosy. This study aims to understanding the pathomechanism of ENL by examined IL-7 and PDGF-BB mRNA expression that can be the development and consideration of new effective therapies to prevent reactions, recurrences, and defects in leprosy. Materials and Methods: The study used a cross-sectional analytic design. Sampling was done by peripheral blood from the patient and measuring mRNA expression with specific primers RT-PCR. Results: The expression of mRNA IL-7 and PDGF-BB was significantly different between multibasilar patients without reaction and with ENL reaction, where there was increased expression in ENL patients. This could be used as the development of potential biomarkers in ENL and development of new therapeutic intervention pathways in ENL.
{"title":"Analysis of interleukin 7 and platelet-derived growth factor BB mRNA expression as potential markers in erythema nodosum leprosum","authors":"Fitri Kadarsih Banjar, Farida Tabri, Sri Vitayani Muchtar, Mochammad Hatta, Khaeruddin Djawad, Farida Ilyas, Sitti Musafirah, Muhammad Nasrum Massi, Agussalim Bukhari, Andi Alfian Zainuddin","doi":"10.4081/dr.2023.9773","DOIUrl":"https://doi.org/10.4081/dr.2023.9773","url":null,"abstract":"Introduction: Erythema Nodosum Leprosum (ENL) is an immunological complication of leprosy characterized by acute inflammation of the skin, nerves, and other organs. Identifying laboratory parameters are important to early diagnosis of leprosy reactions. Various cytokine biomarkers have been examined and only a few studies have reported on angiogenesis in leprosy. This study aims to understanding the pathomechanism of ENL by examined IL-7 and PDGF-BB mRNA expression that can be the development and consideration of new effective therapies to prevent reactions, recurrences, and defects in leprosy. Materials and Methods: The study used a cross-sectional analytic design. Sampling was done by peripheral blood from the patient and measuring mRNA expression with specific primers RT-PCR. Results: The expression of mRNA IL-7 and PDGF-BB was significantly different between multibasilar patients without reaction and with ENL reaction, where there was increased expression in ENL patients. This could be used as the development of potential biomarkers in ENL and development of new therapeutic intervention pathways in ENL.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135879067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Viviana Lora, Arianna Lamberti, Monia Di Prete, Dario Graceffa, Carlo Cota
The pandemic of SARS-CoV-2 during the first years of the 2020s led to a great commitment to develop effective vaccines. Despite of the good safety and tolerability profile, vaccines may trigger a broad spectrum of cutaneous side effects. Granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA vaccines, but no cases of annular elastolytic giant cell granuloma have been already described. Moreover, in our case, it was also associated with a central area of mid-dermal elastolysis, confirming the strong association between these two diseases already reported in literature. The observation of occasional eosinophils within the infiltrate and the presentation of the cutaneous eruption few days after the administration of the second dose of Pfizer/BioNTech (BNT162b2) vaccine are highly suggestive of a drug-related eruption. To our knowledge, this is the first report in literature of an annular elastolytic giant cell granuloma as an adverse effect of SARS-CoV-2 vaccination.
{"title":"Annular elastolytic giant cell granuloma after COVID-19 vaccination","authors":"Viviana Lora, Arianna Lamberti, Monia Di Prete, Dario Graceffa, Carlo Cota","doi":"10.4081/dr.2023.9811","DOIUrl":"https://doi.org/10.4081/dr.2023.9811","url":null,"abstract":"The pandemic of SARS-CoV-2 during the first years of the 2020s led to a great commitment to develop effective vaccines. Despite of the good safety and tolerability profile, vaccines may trigger a broad spectrum of cutaneous side effects. Granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA vaccines, but no cases of annular elastolytic giant cell granuloma have been already described. Moreover, in our case, it was also associated with a central area of mid-dermal elastolysis, confirming the strong association between these two diseases already reported in literature. The observation of occasional eosinophils within the infiltrate and the presentation of the cutaneous eruption few days after the administration of the second dose of Pfizer/BioNTech (BNT162b2) vaccine are highly suggestive of a drug-related eruption. To our knowledge, this is the first report in literature of an annular elastolytic giant cell granuloma as an adverse effect of SARS-CoV-2 vaccination.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135878907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：